BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35294130)

  • 1. Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.
    Xin XL; Wang GD; Han R; Jiang Y; Liu C; Liu LS; Xu ZY
    J Tradit Chin Med; 2022 Feb; 42(1):108-115. PubMed ID: 35294130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
    Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
    Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis.
    Lu M; Fan X; Liao W; Li Y; Ma L; Yuan M; Gu R; Wei Z; Wang C; Zhang H
    BMC Cancer; 2021 May; 21(1):616. PubMed ID: 34039311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
    Liu X; Liu X; Li J; Ren F
    Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome profile and its partly verification of human hepatocellular carcinoma cells exposed to Yuzhizi () seed extract.
    Xiaoyan F; Mingzhe LI; Long C; Chao L; Wenli LU; Zhiqiang P; Dongwei J; Peike P; Zhaoqin F; Xiaomei L
    J Tradit Chin Med; 2022 Dec; 42(6):922-931. PubMed ID: 36378050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data.
    Zhang C; Peng L; Zhang Y; Liu Z; Li W; Chen S; Li G
    Med Oncol; 2017 Jun; 34(6):101. PubMed ID: 28432618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.
    Li J; Liu X; Cui Z; Han G
    Med Sci Monit; 2020 Jun; 26():e922070. PubMed ID: 32578582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
    Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
    J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.
    Wang L; Qu J; Liang Y; Zhao D; Rehman FU; Qin K; Zhang X
    Thorac Cancer; 2020 Apr; 11(4):851-866. PubMed ID: 32059076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model.
    Tian S; Guo Y; Fu J; Li Z; Li J; Tian X
    Comput Math Methods Med; 2022; 2022():3049619. PubMed ID: 35607647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses.
    Song F; Xuan Z; Yang X; Ye X; Pan Z; Fang Q
    J Cell Biochem; 2020 Mar; 121(3):2690-2703. PubMed ID: 31692035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis.
    Piao J; Sun J; Yang Y; Jin T; Chen L; Lin Z
    Gene; 2018 Mar; 647():306-311. PubMed ID: 29305979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of key genes and pathways in pelvic organ prolapse based on gene expression profiling by bioinformatics analysis.
    Zhou Q; Hong L; Wang J
    Arch Gynecol Obstet; 2018 May; 297(5):1323-1332. PubMed ID: 29546564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentially Expressed Gene Screening, Biological Function Enrichment, and Correlation with Prognosis in Non-Small Cell Lung Cancer.
    Huang H; Huang Q; Tang T; Zhou X; Gu L; Lu X; Liu F
    Med Sci Monit; 2019 Jun; 25():4333-4341. PubMed ID: 31181055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
    Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of latent biomarkers in connection with progression and prognosis in oral cancer by comprehensive bioinformatics analysis.
    Reyimu A; Chen Y; Song X; Zhou W; Dai J; Jiang F
    World J Surg Oncol; 2021 Aug; 19(1):240. PubMed ID: 34384424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
    Ma GF; Zhang RF; Ying KJ; Wang D
    Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):578-85. PubMed ID: 25753874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential therapeutic target genes and mechanisms in non-small-cell lung carcinoma in non-smoking women based on bioinformatics analysis.
    Zhou W; Yin M; Cui H; Wang N; Zhao LL; Yuan LZ; Yang XP; Ding XM; Men FZ; Ma X; Na JR
    Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3375-84. PubMed ID: 26439031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLE2 Serves as a Prognostic Biomarker and Is Associated with Immune Infiltration in Squamous Cell Lung Cancer.
    Wu Z; Wang YM; Dai Y; Chen LA
    Med Sci Monit; 2020 Apr; 26():e921430. PubMed ID: 32304567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
    Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
    Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.